To further elucidate the efficacy of SIM administration against lipid metabolism disorders, hepatic mRNA expression levels of BESP, CYP7A1, ACAT2, SREBP-1C, CD36, and HMGCR are investigated. The gene discussed is SREBF1; the disease is Disorder of lipid metabolism.